{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:49:27Z","timestamp":1790495367458,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"French National Agency for Research on AIDS","award":["ANRS 12286\/MOBIDIP"],"award-info":[{"award-number":["ANRS 12286\/MOBIDIP"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The ANRS12286\/MOBIDIP trial showed that boosted protease inhibitor (bPI) plus lamivudine dual therapy was superior to bPI monotherapy as maintenance treatment in subjects with a history of M184V mutation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We aimed to deep analyse the detection of M184V\/I variants at time of switch and at the time of virological failure (VF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Ultra-deep sequencing (UDS) was performed on proviral HIV-DNA at inclusion among 265 patients enrolled in the ANRS 12026\/MOBIDIP trial, and on plasma from 31 patients experiencing VF. The proportion of M184V\/I variants was described and the association between the M184V\/I mutation at 1% of threshold and VF was explored with logistic regression models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>M184V and I mutations were detected in HIV-DNA for 173\/252 (69%) and 31\/252 (12%) of participants, respectively. Longer duration of first-line treatment, higher plasma viral load at first-line treatment failure and higher baseline HIV-DNA load were associated with the archived M184V. M184I mutation was always associated with a STOP codon, suggesting defective virus. The 48\u2009week estimated probability of remaining free from VF was comparable with or without the M184V\/I mutation for dual therapy. At failure, M184V and major PI mutations were detected in 1\/17 and 5\/15 patients in the bPI arm and in 2\/2 and 0\/3 in the bPI+lamivudine arm, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Using UDS evidenced that archiving of M184V in HIV-DNA is heterogeneous despite past historical M184V in 96% of cases. The antiviral efficacy of lamivudine-based dual therapy regimens is mainly due to the residual lamivudine activity.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkab002","type":"journal-article","created":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T12:13:40Z","timestamp":1613304820000},"page":"1286-1293","source":"Crossref","is-referenced-by-count":8,"title":["Deep sequencing analysis of M184V\/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial)"],"prefix":"10.1093","volume":"76","author":[{"given":"Constance","family":"Delaugerre","sequence":"first","affiliation":[{"name":"Department of Virology, H\u00f4pital Saint Louis, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"INSERM U944, University of Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Nere","sequence":"additional","affiliation":[{"name":"Department of Virology, H\u00f4pital Saint Louis, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Eymard-Duvernay","sequence":"additional","affiliation":[{"name":"TransVIHMI, Institut de Recherche pour le D\u00e9veloppement (IRD) \u2013 INSERM U1175 University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Armero","sequence":"additional","affiliation":[{"name":"Department of Virology, H\u00f4pital Saint Louis, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ciaffi","sequence":"additional","affiliation":[{"name":"TransVIHMI, Institut de Recherche pour le D\u00e9veloppement (IRD) \u2013 INSERM U1175 University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinata","family":"Koulla-Shiro","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Central Hospital Yaound\u00e9, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Sawadogo","sequence":"additional","affiliation":[{"name":"Day Care Center, University Hospital Souro Sanou, Bobo Dioulasso, Burkina Faso"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ndaye Fatou","family":"Ngom Gueye","sequence":"additional","affiliation":[{"name":"Day Care Center, Fann University Hospital, Dakar, Senegal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheik Tidiane","family":"Ndour","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Fann University Hospital, Dakar, Senegal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Mpoudi Ngolle","sequence":"additional","affiliation":[{"name":"Ambulatory Treatment Center, Military Hospital Yaound\u00e9, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Amara","sequence":"additional","affiliation":[{"name":"INSERM U944, University of Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Chaix","sequence":"additional","affiliation":[{"name":"Department of Virology, H\u00f4pital Saint Louis, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"INSERM U944, University of Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Reynes","sequence":"additional","affiliation":[{"name":"TransVIHMI, Institut de Recherche pour le D\u00e9veloppement (IRD) \u2013 INSERM U1175 University of Montpellier, Montpellier, France"},{"name":"Department of Infectious Diseases, Montpellier University Hospital, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ANRS 12286\/MOBIDIP study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"2021041608542478000_dkab002-B1","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1093\/jac\/dky299","article-title":"Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: geSIDA study 9717","volume":"73","author":"Perez-Molina","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021041608542478000_dkab002-B2","doi-asserted-by":"crossref","first-page":"e384\u201392","DOI":"10.1016\/S2352-3018(17)30069-3","article-title":"Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286\/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial","volume":"4","author":"Ciaffi","year":"2017","journal-title":"Lancet HIV"},{"key":"2021041608542478000_dkab002-B3","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1126\/science.271.5253.1282","article-title":"Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase","volume":"271","author":"Wainberg","year":"1996","journal-title":"Science"},{"key":"2021041608542478000_dkab002-B4","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1128\/JVI.02154-08","article-title":"In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine","volume":"83","author":"Paredes","year":"2009","journal-title":"J Virol"},{"key":"2021041608542478000_dkab002-B5","doi-asserted-by":"crossref","first-page":"e638\u201346","DOI":"10.1016\/S2352-3018(18)30177-2","article-title":"Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study","volume":"5","author":"Inzaule","year":"2018","journal-title":"Lancet HIV"},{"key":"2021041608542478000_dkab002-B6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QAI.0b013e3182a009e4","article-title":"Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in C\u00f4te d\u2019Ivoire, West Africa","volume":"64","author":"Messou","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021041608542478000_dkab002-B7","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/QAI.0b013e3182084b5a","article-title":"Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in C\u00f4te d\u2019Ivoire","volume":"56","author":"Messou","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021041608542478000_dkab002-B8","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1089\/aid.2016.0010","article-title":"Short communication: high viral load and multidrug resistance due to late switch to second-line regimens could be a major obstacle to reach the 90\u201390\u201390 UNAIDS Objectives in Sub-Saharan Africa","volume":"32","author":"Guichet","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2021041608542478000_dkab002-B9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2021041608542478000_dkab002-B10","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1093\/jac\/dky315","article-title":"Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia","volume":"73","author":"Rodriguez","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021041608542478000_dkab002-B11","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/jac\/dkx233","article-title":"HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir\u2009+\u2009lamivudine in the maintenance DOLULAM pilot study","volume":"72","author":"Charpentier","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021041608542478000_dkab002-B12","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/jac\/dky130","article-title":"Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART","volume":"73","author":"Nouchi","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021041608542478000_dkab002-B13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/430709","article-title":"Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection","volume":"41","author":"Campbell","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2021041608542478000_dkab002-B14","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/infdis\/jiz631","article-title":"Human immunodeficiency virus-1 viral load is elevated in individuals with reverse-transcriptase mutation M184V\/I during virological failure of first-line antiretroviral therapy and is associated with compensatory mutation L74I","volume":"222","author":"Gregson","year":"2020","journal-title":"J Infect Dis"},{"key":"2021041608542478000_dkab002-B15","doi-asserted-by":"crossref","first-page":"ofy113","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2021041608542478000_dkab002-B16","doi-asserted-by":"crossref","first-page":"ofz330","DOI":"10.1093\/ofid\/ofz330","article-title":"Impact of the M184V\/I mutation on the efficacy of abacavir\/lamivudine\/dolutegravir therapy in HIV treatment-experienced patients","volume":"6","author":"Olearo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021041608542478000_dkab002-B17","doi-asserted-by":"crossref","first-page":"102779","DOI":"10.1016\/j.ebiom.2020.102779","article-title":"Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)","volume":"55","author":"De Miguel","year":"2020","journal-title":"EBioMedicine"},{"key":"2021041608542478000_dkab002-B18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cmi.2015.10.004","article-title":"Contribution of APOBEC3G\/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants","volume":"22","author":"Noguera-Julian","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2021041608542478000_dkab002-B19","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/cid\/ciy589","article-title":"Evolution of protease inhibitor resistance in human immunodeficiency virus type 1 infected patients failing protease inhibitor monotherapy as second-line therapy in low-income countries: an observational analysis within the EARNEST randomized trial","volume":"68","author":"Thompson","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021041608542478000_dkab002-B20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/135965350901400105","article-title":"Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone","volume":"14","author":"Flandre","year":"2009","journal-title":"Antivir Ther"},{"key":"2021041608542478000_dkab002-B21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jac\/dku365","article-title":"HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir\/ritonavir","volume":"70","author":"Sutherland","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2021041608542478000_dkab002-B22","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1093\/jac\/dku296","article-title":"Phenotypic characterization of virological failure following lopinavir\/ritonavir monotherapy using full-length gag-protease genes","volume":"69","author":"Sutherland","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2021041608542478000_dkab002-B23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(15)00096-1","article-title":"Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial","volume":"15","author":"Arribas","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2021041608542478000_dkab002-B24","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/cix734","article-title":"Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppression: randomized, open-label, noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial","volume":"65","author":"Pulido","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021041608542478000_dkab002-B25","first-page":"1163","article-title":"Treatment simplification to atazanavir\/ritonavir\u2009+\u2009lamivudine versus maintenance of atazanavir\/ritonavir\u2009+\u2009two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)","volume":"72","author":"Di Giambenedetto","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021041608542478000_dkab002-B26","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(15)00097-3","article-title":"Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial","volume":"15","author":"Perez-Molina","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2021041608542478000_dkab002-B27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/23744235.2017.1410285","article-title":"Simplification to dual-therapy containing lamivudine and darunavir\/ritonavir or atazanavir\/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy","volume":"50","author":"Calza","year":"2018","journal-title":"Infect Dis (Lond)"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/5\/1286\/37042048\/dkab002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/5\/1286\/37042048\/dkab002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T09:08:32Z","timestamp":1671268112000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/5\/1286\/6148905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,2,24]]},"published-print":{"date-parts":[[2021,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab002","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,2,24]]}}}